Skip header and navigation

Refine By

3 records – page 1 of 1.

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.

https://arctichealth.org/en/permalink/ahliterature176202
Source
Contraception. 2005 Feb;71(2):111-7
Publication Type
Article
Date
Feb-2005
Author
Sven O Skouby
Jan Endrikat
Bernd Düsterberg
Werner Schmidt
Christoph Gerlinger
Jens Wessel
Henri Goldstein
Joergen Jespersen
Author Affiliation
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark. sven.skouby@fh.hosp.dk
Source
Contraception. 2005 Feb;71(2):111-7
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
Adult
Blood Glucose - metabolism
C-Peptide - blood
Carbohydrate Metabolism - drug effects
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Contraceptive Agents, Female - administration & dosage - pharmacology
Contraceptives, Oral, Combined - administration & dosage - pharmacology
Denmark
Dose-Response Relationship, Drug
Ethinyl Estradiol - administration & dosage - pharmacology
Fatty Acids, Nonesterified - blood
Female
Humans
Insulin - blood
Levonorgestrel - administration & dosage - pharmacology
Lipid Metabolism - drug effects
Prospective Studies
Time Factors
Treatment Outcome
Triglycerides - blood
Abstract
To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
In an open-label, randomized study, a dose-reduced oral contraceptive containing 20 microg EE and 100 microg LNG (20 EE/100 LNG) was compared with a reference preparation containing 30 microg EE and 150 microg LNG (30 EE/150 LNG). One-year data from 48 volunteers were obtained.
We found a decrease of HDL2 cholesterol and increases of low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides in both treatment groups from baseline to the 13th treatment cycle. Although for four of six variables, the changes in the 20 EE group were lower compared with the 30 EE group, none of the differences between the two treatments were statistically significant. The median values for the fasting levels of insulin, C-peptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles. While the glucose area under the curve (AUC) (0-3 h) was similar in both groups during the OGTT, the insulin AUC(0-3 h) was less increased in the 20 EE/100 LNG group compared with the 30 EE/150 LNG group. None of the differences between the treatment groups for any of the carbohydrate metabolism variables were statistically significant at any time point. Both study treatments were safe and well tolerated by the volunteers.
Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
PubMed ID
15707560 View in PubMed
Less detail

A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.

https://arctichealth.org/en/permalink/ahliterature161601
Source
Eur J Contracept Reprod Health Care. 2007 Sep;12(3):220-8
Publication Type
Article
Date
Sep-2007
Author
Jan Endrikat
Mirella Sandri
Christoph Gerlinger
Alexander Rübig
Werner Schmidt
Michel Fortier
Author Affiliation
Bayer Inc., Toronto, Ontario, Canada. jan.endrikat.b@bayer.com
Source
Eur J Contracept Reprod Health Care. 2007 Sep;12(3):220-8
Date
Sep-2007
Language
English
Publication Type
Article
Keywords
Adult
Androstenes - pharmacology - therapeutic use
Body Water - drug effects - physiology
Body Weight - drug effects - physiology
Canada
Contraceptives, Oral, Combined
Edema - chemically induced - physiopathology - psychology
Ethinyl Estradiol - pharmacology - therapeutic use
Female
Humans
Mineralocorticoid Receptor Antagonists - pharmacology - therapeutic use
Premenstrual Syndrome - chemically induced - diagnosis - physiopathology - psychology
Prospective Studies
Questionnaires
Severity of Illness Index
Abstract
To evaluate the effects of an oral contraceptive containing 3 mg drospirenone (DRSP) and 30 microg ethinyl oestradiol (EE) on somatic and psychological symptoms related to water retention, and on body weight.
This prospective study was performed in 26 centres in Canada over six treatment cycles. The first primary efficacy variable was the individual change in the water retention score of the Moos Menstrual Distress Questionnaire (MDQ) from baseline to the final examination in women with significant somatic symptoms related to water retention (n = 43). The second primary target variable was the change in body weight (n = 305).
Forty-three women met the criteria for the first primary target variable. In the premenstrual phase, the score decreased from 6.49 (SEM 0.45) at baseline to 3.19 (SEM 0.54) at the final examination (p = 0.0001). The data for the menstrual phase were 4.70 (SEM 0.30) at baseline and 2.35 (SEM 0.32) at the final examination (p
PubMed ID
17763260 View in PubMed
Less detail

A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia.

https://arctichealth.org/en/permalink/ahliterature150542
Source
J Obstet Gynaecol Can. 2009 Apr;31(4):340-7
Publication Type
Article
Date
Apr-2009
Author
Jan Endrikat
Heather Shapiro
Eeva Lukkari-Lax
Michael Kunz
Werner Schmidt
Michel Fortier
Author Affiliation
Bayer Inc., Toronto, Ontario, Canada.
Source
J Obstet Gynaecol Can. 2009 Apr;31(4):340-7
Date
Apr-2009
Language
English
Publication Type
Article
Keywords
Adult
Canada
Contraceptive Agents, Female - administration & dosage
Contraceptives, Oral, Synthetic - therapeutic use
Estrogens - therapeutic use
Ethinyl Estradiol - therapeutic use
Female
Hemoglobins - analysis
Humans
Intrauterine Devices, Medicated
Levonorgestrel - administration & dosage
Menorrhagia - drug therapy
Norethindrone - analogs & derivatives - therapeutic use
Prospective Studies
Severity of Illness Index
Abstract
To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (MBL) in women with idiopathic menorrhagia.
A prospective, randomized, open-label study was conducted in nine centres in Canada. Healthy women over 30 years of age suffering from idiopathic menorrhagia were treated either with LNG-IUS (n = 20) or with OC1/20 (n = 19) over 12 months. The primary endpoint was the change in MBL from baseline to 12 months. Secondary endpoints included treatment success (defined as a MBL score
PubMed ID
19497153 View in PubMed
Less detail